Experimental treatment doesn’t cut viral load in nonhospitalized patients with mild to moderate symptoms; stock plunges 61%
Doctors are increasingly turning to monoclonal antibody drugs to treat high-risk patients who get sick with Covid-19. WSJ takes a look at how the therapies work and why they’re important for saving lives. Illustration: Jacob Reynolds/WSJ
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more: